{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:36:10Z","timestamp":1791894970677,"version":"4.3.4"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004778","name":"NIKE","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.metabol.2017.09.013","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T12:34:39Z","timestamp":1507811679000},"page":"141-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes"],"prefix":"10.1016","volume":"78","author":[{"given":"Marco","family":"Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Muscogiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Felicetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antongiulio","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Arvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0005","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.22717","article-title":"Diabetes mellitus and risk of breast cancer: a meta-analysis","volume":"121","author":"Larsson","year":"2007","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.metabol.2017.09.013_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.metabol.2017.09.013_bb0015","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/sj.bjc.6602619","article-title":"Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies","volume":"92","author":"Huxley","year":"2005","journal-title":"Br J Cancer"},{"issue":"22","key":"10.1016\/j.metabol.2017.09.013_bb0020","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/jnci\/dji375","article-title":"Diabetes mellitus and risk of colorectal cancer: a meta-analysis","volume":"97","author":"Larsson","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.metabol.2017.09.013_bb0025","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00125-006-0468-0","article-title":"Diabetes mellitus and risk of bladder cancer: a meta-analysis","volume":"49","author":"Larsson","year":"2006","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.metabol.2017.09.013_bb0030","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00125-007-0681-5","article-title":"Diabetes mellitus and risk of endometrial cancer: a meta-analysis","volume":"50","author":"Friberg","year":"2007","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.metabol.2017.09.013_bb0035","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2337\/dc08-1034","article-title":"Diabetes and risk of non-Hodgkin's lymphoma: meta-analysis of observational studies","volume":"31","author":"Mitri","year":"2008","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2017.09.013_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2012.40","article-title":"Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies","volume":"16","author":"Bansal","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.metabol.2017.09.013_bb0045","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.metabol.2014.07.006","article-title":"Association between fasting serum glucose levels and incidence of colorectal cancer in Korean men: the Korean Cancer Prevention Study-II","volume":"63","author":"Shin","year":"2014","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.metabol.2017.09.013_bb0050","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.numecd.2013.05.006","article-title":"Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients","volume":"23","author":"Sciacca","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.metabol.2017.09.013_bb0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.metabol.2014.10.008","article-title":"Metabolic syndrome and risk of cancer: which link?","volume":"64","author":"Mendon\u00e7a","year":"2015","journal-title":"Metabolism"},{"issue":"23","key":"10.1016\/j.metabol.2017.09.013_bb0060","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/djg105","article-title":"Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden","volume":"95","author":"Zendehdel","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.metabol.2017.09.013_bb0065","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-016-3884-9","article-title":"Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals","volume":"59","author":"Carstensen","year":"2016","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.metabol.2017.09.013_bb0070","first-page":"269","article-title":"Menstrual characteristics of women suffering from insulin-dependent diabetes mellitus","volume":"40","author":"Yeshaya","year":"1995","journal-title":"Int J Fertil Menopausal Stud"},{"issue":"6","key":"10.1016\/j.metabol.2017.09.013_bb0075","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<784::AID-IJC2>3.0.CO;2-U","article-title":"Role of reproductive factors on the risk of endometrial cancer","volume":"76","author":"Parazzini","year":"1998","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.metabol.2017.09.013_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/BF02282318","article-title":"High seroprevalence of Helicobacter pylori in diabetes mellitus patients","volume":"41","author":"Oldenburg","year":"1996","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.metabol.2017.09.013_bb0085","first-page":"4062","article-title":"High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry","volume":"84","author":"De Block","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.metabol.2017.09.013_bb0090","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.metabol.2017.09.013_bb0095","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00125-014-3361-2","article-title":"Prediabetes and the risk of cancer: a meta-analysis","volume":"57","author":"Huang","year":"2014","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0100","first-page":"207","article-title":"Diabetes and cancer: a consensus report","volume":"60","author":"Giovannucci","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.metabol.2017.09.013_bb0105","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00125-010-1796-7","article-title":"Diabetes, prediabetes and cancer mortality","volume":"53","author":"Zhou","year":"2010","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.metabol.2017.09.013_bb0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diaspect.19.3.157","article-title":"Clinical challenges in caring for patients with diabetes and cancer","volume":"19","author":"Psarakis","year":"2006","journal-title":"Diabetes Spectr"},{"issue":"5","key":"10.1016\/j.metabol.2017.09.013_bb0115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00125-014-3186-z","article-title":"Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment","volume":"57","author":"Ranc","year":"2014","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0120","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc09-1721","article-title":"Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis","volume":"33","author":"Barone","year":"2010","journal-title":"Diabetes Care"},{"issue":"104","key":"10.1016\/j.metabol.2017.09.013_bb0125","doi-asserted-by":"crossref","first-page":"104ra101","DOI":"10.1126\/scitranslmed.3002191","article-title":"Diabetes impairs hematopoietic stem cell mobilization by altering niche function","volume":"3","author":"Ferraro","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.metabol.2017.09.013_bb0130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/cncr.20071","article-title":"Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone\/methotrexate-cytarabine regimen","volume":"100","author":"Weiser","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4158\/EP13248.CS","article-title":"Diabetes and cancer: an AACE\/ACE consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2017.09.013_bb0140","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.diabres.2014.09.027","article-title":"Diabetes and cancer mortality: a multifaceted association","volume":"106","author":"Fedeli","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2017.09.013_bb0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/jsre.2002.6449","article-title":"The need for a multidisciplinary approach to cancer care","volume":"105","author":"Ko","year":"2002","journal-title":"J Surg Res"},{"key":"10.1016\/j.metabol.2017.09.013_bb0150","first-page":"244","article-title":"Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines","volume":"14","author":"McCoubrie","year":"2015","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.metabol.2017.09.013_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/583786","article-title":"Diabetes and risk of cancer","author":"Habib","year":"2013","journal-title":"ISRN Oncol"},{"issue":"2","key":"10.1016\/j.metabol.2017.09.013_bb0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrclinonc.2016.120","article-title":"Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?","volume":"14","author":"Klil-Drori","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0165","series-title":"2013 ESMO handbook on cancer treatment in special clinical situations","first-page":"72","article-title":"Cancer treatment in patients with diabetes","author":"Mateo","year":"2013"},{"key":"10.1016\/j.metabol.2017.09.013_bb0170","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/390863","article-title":"Diabetes and its link with cancer: providing the fuel and spark to launch an aggressive growth regime","author":"Joshi","year":"2015","journal-title":"Biomed Res Int"},{"issue":"8","key":"10.1016\/j.metabol.2017.09.013_bb0175","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.metabol.2016.01.010","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma","volume":"65","author":"Zoller","year":"2016","journal-title":"Metabolism"},{"issue":"3191","key":"10.1016\/j.metabol.2017.09.013_bb0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.metabol.2017.09.013_bb0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/cdd.2013.131","article-title":"Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway","volume":"21","author":"Liu","year":"2014","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13402-016-0282-8","article-title":"High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells","volume":"39","author":"Flores-L\u00f3pez","year":"2016","journal-title":"Cell Oncol (Dordr)"},{"issue":"10","key":"10.1016\/j.metabol.2017.09.013_bb0195","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00018-015-1840-3","article-title":"Dysregulated glycolysis as an oncogenic event","volume":"72","author":"Mikawa","year":"2015","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10.1016\/j.metabol.2017.09.013_bb0200","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.metabol.2015.07.005","article-title":"Inhibition of tumor energy pathways for targeted esophagus cancer therapy","volume":"64","author":"Shafaee","year":"2015","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.metabol.2017.09.013_bb0205","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1172\/JCI114868","article-title":"Elevated insulin receptor content in human breast cancer","volume":"86","author":"Papa","year":"1990","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.metabol.2017.09.013_bb0210","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/MCB.19.5.3278","article-title":"Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells","volume":"19","author":"Frasca","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.metabol.2017.09.013_bb0215","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/er.2008-0047","article-title":"Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease","volume":"30","author":"Belfiore","year":"2009","journal-title":"Endocr Rev"},{"issue":"17","key":"10.1016\/j.metabol.2017.09.013_bb0220","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2017.09.013_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.numecd.2005.10.013","article-title":"Obesity and cancer","volume":"16","author":"Vigneri","year":"2006","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2017.09.013_bb0230","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0235","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1210\/er.2011-1015","article-title":"The role of adiponectin in cancer: a review of current evidence","volume":"33","author":"Dalamaga","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2017.09.013_bb0240","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","article-title":"The c-Myc target gene network","volume":"16","author":"Dang","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.metabol.2017.09.013_bb0250","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1073\/pnas.1507228112","article-title":"MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism","volume":"112","author":"Shroff","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nm.4055","article-title":"Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer","volume":"22","author":"Camarda","year":"2016","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.metabol.2017.09.013_bb0260","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MPH.0b013e3181b794e8","article-title":"Acute pancreatitis in children with acute lymphoblastic leukemia treated with l-asparaginase","volume":"31","author":"Flores-Calder\u00f3n","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.metabol.2017.09.013_bb0265","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1749-6632.1968.tb19055.x","article-title":"Clinical use of diazoxide and studies of the mechanism of its hyperglycemic effects in man","volume":"150","author":"Graber","year":"1968","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.metabol.2017.09.013_bb0270","first-page":"817","article-title":"Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study","volume":"35","author":"Faggiano","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"10.1016\/j.metabol.2017.09.013_bb0275","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.metabol.2017.09.013_bb0280","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.metabol.2017.09.013_bb0285","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","article-title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.metabol.2017.09.013_bb0290","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.metabol.2017.09.013_bb0295","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.metabol.2017.09.013_bb0300","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2017.09.013_bb0305","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0310","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","article-title":"Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab","volume":"4","author":"Weber","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.metabol.2017.09.013_bb0315","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/dmrr.2486","article-title":"Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment","volume":"30","author":"Hwang","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.metabol.2017.09.013_bb0320","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1188\/14.ONF.E355-E365","article-title":"Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review","volume":"41","author":"Brady","year":"2014","journal-title":"Oncol Nurs Forum"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0325","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ctrv.2015.02.007","article-title":"Cancer-drug induced insulin resistance: innocent bystander or unusual suspect","volume":"41","author":"Ariaans","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"10.1016\/j.metabol.2017.09.013_bb0330","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/archinte.1997.00440360053005","article-title":"Glucocorticoid like activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature","volume":"157","author":"Mann","year":"1997","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.metabol.2017.09.013_bb0335","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-013-2630-y","article-title":"Everolimus: side effect profile and management of toxicities in breast cancer","volume":"140","author":"Paplomata","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.metabol.2017.09.013_bb0340","series-title":"SEER cancer statistics review, 1975\u20132013","author":"Howlader","year":"2013"},{"issue":"15","key":"10.1016\/j.metabol.2017.09.013_bb0345","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Childhood cancer survivor study. Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2017.09.013_bb0350","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/ijc.29135","article-title":"Late mortality among 5-year survivors of early onset cancer: a population-based register study","volume":"136","author":"Kero","year":"2015","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1016\/j.metabol.2017.09.013_bb0355","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.metabol.2017.09.013_bb0360","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1470-2045(09)70287-6","article-title":"The metabolic syndrome in cancer survivors","volume":"11","author":"de Haas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0365","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/2047487314529348","article-title":"Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16years follow up from a prospective registry","volume":"22","author":"Felicetti","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0370","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1200\/JCO.2010.34.4267","article-title":"Risk factors for obesity in adult survivors of childhood cancer: a report from the childhood cancer survivor study","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0375","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0380","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.metabol.2017.09.013_bb0385","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.2013.54.4379","article-title":"Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma","volume":"32","author":"van Nimwegen","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0390","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2006-05-022335","article-title":"Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study","volume":"109","author":"Baker","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.metabol.2017.09.013_bb0395","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bbmt.2009.05.010","article-title":"Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation","volume":"15","author":"Majhail","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.metabol.2017.09.013_bb0400","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/pbc.25601","article-title":"Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell transplantation is associated with lipodystropic and sarcopenic phenotypes","volume":"62","author":"Wei","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.metabol.2017.09.013_bb0405","doi-asserted-by":"crossref","first-page":"djv402","DOI":"10.1093\/jnci\/djv402","article-title":"Incidence of diabetes in colorectal cancer survivors","volume":"108","author":"Singh","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.metabol.2017.09.013_bb0410","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00125-012-2793-9","article-title":"Incidence of diabetes among postmenopausal breast cancer survivors","volume":"56","author":"Lipscombe","year":"2013","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0415","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1097\/MPH.0000000000000320","article-title":"Institutional adherence to cardiovascular risk factor screening guidelines for young survivors of acute lymphoblastic leukemia","volume":"37","author":"Lin","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0420","author":"The Children's Oncology Group"},{"issue":"8","key":"10.1016\/j.metabol.2017.09.013_bb0425","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bbmt.2016.05.007","article-title":"Metabolic syndrome and cardiovascular disease after hematopoietic cell transplantation: screening and preventive practice recommendations from the CIBMTR and EBMT","volume":"22","author":"DeFilipp","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.metabol.2017.09.013_bb0430","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1530\/EJE-12-1043","article-title":"Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics","volume":"168","author":"Brignardello","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0435","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0885-3924(96)00326-0","article-title":"The management of diabetes in patients with advanced cancer","volume":"13","author":"Poulson","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.metabol.2017.09.013_bb0440","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2017.09.013_bb0445","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jso.24133","article-title":"Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma","volume":"113","author":"Lee","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0450","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/qjmed\/hcu218","article-title":"Management of diabetes in patients with cancer","volume":"108","author":"Jacob","year":"2015","journal-title":"QJM"},{"key":"10.1016\/j.metabol.2017.09.013_bb0455","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.metabol.2017.09.013_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The frailty syndrome: definition and natural history","volume":"27","author":"Xue","year":"2011","journal-title":"Clin Geriatr Med"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2017.09.013_bb0465","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.2337\/dc17-S009","article-title":"Standards of medical care in diabetes-2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"issue":"Suppl. 3","key":"10.1016\/j.metabol.2017.09.013_bb0470","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1262-3636(11)70962-4","article-title":"European diabetes working party for older people 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary","volume":"37","author":"Sinclair","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2017.09.013_bb0475","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence","author":"Heckman-Stoddard","year":"2017","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.metabol.2017.09.013_bb0480","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/14740338.2015.1084289","article-title":"Metformin: risk-benefit profile with a focus on cancer","volume":"14","author":"Provinciali","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.metabol.2017.09.013_bb0485","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1634\/theoncologist.2013-0111","article-title":"Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Yin","year":"2013","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.metabol.2017.09.013_bb0490","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/onc.2012.181","article-title":"Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects","volume":"32","author":"Pierotti","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.metabol.2017.09.013_bb0495","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.maturitas.2017.04.001","article-title":"Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus","volume":"101","author":"Perez-Lopez","year":"2017","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.metabol.2017.09.013_bb0500","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jc.2012-3249","article-title":"Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension","volume":"98","author":"Mathieu","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0505","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2017.09.013_bb0510","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/dia.2015.0290","article-title":"Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300U\/mL in people with type 2 diabetes","volume":"18","author":"Riddle","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2017.09.013_bb0515","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.09.013_bb0520","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1517\/14656566.2015.1102887","article-title":"Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib","volume":"16","author":"Casadei Gardini","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.metabol.2017.09.013_bb0525","first-page":"989","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy\u2013focus on alogliptin","volume":"7","author":"Capuano","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.metabol.2017.09.013_bb0530","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.metabol.2017.09.013_bb0535","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2017.09.013_bb0540","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1049909114533140","article-title":"Diabetes management in end of life: a preliminary report stemming from clinical experience","volume":"32","author":"Dionisio","year":"2015","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.metabol.2017.09.013_bb0545","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00592-016-0839-z","article-title":"Diabetology and oncology meet in a network model: union is strength","volume":"53","author":"Gallo","year":"2016","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.metabol.2017.09.013_bb0550","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamainternmed.2015.0328","article-title":"Evidence-based deprescribing of statins in patients with advanced illness","volume":"175","author":"Holmes","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.metabol.2017.09.013_bb0555","author":"Pan Birmingham Cancer Network"},{"key":"10.1016\/j.metabol.2017.09.013_bb0560","author":"Diabetes UK"},{"key":"10.1016\/j.metabol.2017.09.013_bb0565","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SPC.0000000000000095","article-title":"Glycaemic control in end-of-life care: fundamental or futile?","volume":"8","author":"Lindskog","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2017.09.013_bb0570","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.2337\/dc17-S014","article-title":"Older adults. Sec. 11. In standards of medical care in diabetes 2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517302652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517302652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:17:37Z","timestamp":1758428257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517302652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":114,"alternative-id":["S0026049517302652"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.09.013","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}